PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Texas Instruments Incorporated (TXN)
205.980.01 (0.00%)
205.24 - 207.41
139.95 - 221.69
4.54M / 6.54M (Avg.)
37.59 | 5.48
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-26.45%
Negative revenue growth while MRVL stands at 11.40%. Joel Greenblatt would look for strategic missteps or cyclical reasons.
-33.23%
Negative gross profit growth while MRVL is at 12.16%. Joel Greenblatt would examine cost competitiveness or demand decline.
-87.40%
Both companies show negative EBIT growth. Martin Whitman would consider macro or sector-specific headwinds.
-93.30%
Both companies face negative operating income growth. Martin Whitman would suspect broader market or cost hurdles.
-80.99%
Negative net income growth while MRVL stands at 120.09%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.
-79.07%
Negative EPS growth while MRVL is at 120.18%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.
-79.07%
Negative diluted EPS growth while MRVL is at 120.18%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.
-1.76%
Both firms reduce share counts. Martin Whitman would compare buyback intensity relative to free cash flow generation.
-2.28%
Both reduce diluted shares. Martin Whitman would review each firm’s ability to continue repurchases and manage option issuance.
9.57%
Dividend growth of 9.57% while MRVL is flat. Bruce Berkowitz would see if this can become a bigger advantage long term.
6.27%
OCF growth under 50% of MRVL's 562.36%. Michael Burry might suspect questionable revenue recognition or rising costs.
21.75%
FCF growth under 50% of MRVL's 2269.09%. Michael Burry would suspect weaker operating efficiencies or heavier capex burdens.
121.43%
10Y revenue/share CAGR under 50% of MRVL's 727.27%. Michael Burry would suspect a lasting competitive disadvantage.
81.93%
5Y revenue/share CAGR under 50% of MRVL's 352.44%. Michael Burry would suspect a significant competitive gap or product weakness.
-13.17%
Negative 3Y CAGR while MRVL stands at 126.82%. Joel Greenblatt would look for missteps or fading competitiveness that hurt sales.
367.14%
10Y OCF/share CAGR under 50% of MRVL's 3151.63%. Michael Burry would worry about a persistent underperformance in cash creation.
111.98%
Below 50% of MRVL's 678.59%. Michael Burry would be alarmed about sustained underperformance in generating free operational cash.
54.17%
3Y OCF/share CAGR under 50% of MRVL's 120.18%. Michael Burry would worry about a significant short-term disadvantage in generating operational cash.
0.30%
Below 50% of MRVL's 100.24%. Michael Burry would worry about a sizable gap in long-term profitability gains vs. the competitor.
-57.80%
Negative 5Y net income/share CAGR while MRVL is 104.31%. Joel Greenblatt would see fundamental missteps limiting profitability vs. the competitor.
-79.55%
Both companies show negative 3Y net income/share growth. Martin Whitman suspects macro or sector-specific headwinds in the short run.
153.14%
Positive growth while MRVL is negative. John Neff might see a strong advantage in steadily compounding net worth over a decade.
59.03%
5Y equity/share CAGR 1.25-1.5x MRVL's 41.35%. Bruce Berkowitz confirms if reinvested profits or buybacks explain the superior buildup.
-2.17%
Negative 3Y equity/share growth while MRVL is at 24.81%. Joel Greenblatt demands an urgent fix in capital structure or profitability vs. the competitor.
656.97%
Dividend/share CAGR of 656.97% while MRVL is zero. Bruce Berkowitz sees a slight advantage in stepping up payouts steadily.
692.36%
Dividend/share CAGR of 692.36% while MRVL is zero. Bruce Berkowitz sees a minor advantage in stepping up distributions, even modestly.
267.82%
3Y dividend/share CAGR of 267.82% while MRVL is zero. Bruce Berkowitz sees a minor positive difference that could attract dividend-focused investors.
-48.53%
Both reduce receivables yoy. Martin Whitman suspects a shift in the entire niche’s credit approach or softer demand.
-12.70%
Inventory is declining while MRVL stands at 9.96%. Joel Greenblatt sees potential cost and margin benefits if sales hold up.
-4.36%
Negative asset growth while MRVL invests at 1.82%. Joel Greenblatt checks if the competitor might capture more market share unless our returns remain higher.
-5.95%
We have a declining book value while MRVL shows 3.26%. Joel Greenblatt sees a fundamental disadvantage in net worth creation vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
-14.99%
Our R&D shrinks while MRVL invests at 5.65%. Joel Greenblatt checks if we risk falling behind a competitor’s new product pipeline.
-7.18%
We cut SG&A while MRVL invests at 37.85%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.